Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia
Case Reports in Cardiology, 2020 Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case.
Amer Aljundi, Alaa Rahhal, Wafer Dabdoob
doaj +1 more source
BMC Cardiovascular Disorders, 2002 Background GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Giusti Andrea, Bertuglia Silva
doaj +1 more source
P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity [PDF]
, 2014 Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein (GP) IIb‐IIIa antagonists, but their combined effect on platelet function and ...
Barnard, Marc R. +5 more
core +1 more source
Journal of Clinical and Preventive Cardiology, 2021 Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal +2 more
doaj +1 more source
Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome [PDF]
, 2006 The purpose of this study is to explain the rationale for the value of information approach to priority setting for research and to describe the methods intuitively for those familiar with basic decision analytical modeling.
Bojke, L. +4 more
core +1 more source
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. [PDF]
, 2004 AIM: To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute ...
Akkerhuis, K.M. (Martijn) +15 more
core +7 more sources
A rare case of eptifibatide-induced thrombocytopenia
Journal of Community Hospital Internal Medicine Perspectives, 2021 Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar +4 more
doaj +1 more source
Structural basis for pure antagonism of integrin αVβ3 by a high affinity form of fibronectin [PDF]
, 2014 Integrins are important therapeutic targets. However, current RGD-based anti-integrin drugs are also partial agonists, inducing conformational changes that trigger potentially fatal immune reactions and paradoxical cell adhesion.
Adair, Brian D. +6 more
core +1 more source
How safe is eptifibatide during urgent carotid artery stenting?
Frontiers in Neurology, 2013 Background: Glycoprotein IIB/IIIA inhibitors are occasionally utilized during carotid artery stenting (CAS) in the presence or absence of a visualized intra-operative thrombus. Objective: We assess the hemorrhagic and clinical outcomes associated with
Hesham eAllam +7 more
doaj +1 more source
Recreation of the terminal events in physiological integrin activation. [PDF]
, 2010 Increased affinity of integrins for the extracellular matrix (activation) regulates cell adhesion and migration, extracellular matrix assembly, and mechanotransduction.
Bobkov, Andrey A +8 more
core +3 more sources